Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma

Mise à jour : Il y a 4 ans
Référence : NCT02923531

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is safe and tolerable. Secondly, the study will investigate if adding X4P-001 to nivolumab treatment has an effect on the body and the cancer tumor, in patients receiving nivolumab but not exhibiting a radiological response.


Critère d'inclusion

  • Clear Cell Renal Cell Carcinoma

Liens